Expert Insight: Intact mass spectrometry of therapeutic proteins

Join us on Tuesday, June 9, to explore the qualitative and quantitative characterization of mAb and protein stability, both in vitro and in vivo, by CE-MS and LC-MS

01 Jun 2020


Protein therapeutics of increasing complexity are playing a growing role in the pharmaceutical market. As a result, understanding the absorption, distribution, metabolism, and excretion (ADME) of proteins has become more important to enable engineering strategies designed to optimize the therapeutic properties of candidate molecules.

Mei Han Senior Scientist, Pharmacokinetics & Drug Metabolism Amgen Inc.
Mei Han, Senior Scientist, Pharmacokinetics & Drug Metabolism at Amgen Inc.

It is important to have robust methods, such as mass spectrometry, to characterize potential instability across a variety of sample types.

Despite the benefits of intact protein mass spectrometry, analysis from serum remains challenging.

This expert webinar, presented by Mei Han, Senior Scientist, Pharmacokinetics & Drug Metabolism at Amgen, will describe the qualitative and quantitative characterization of mAb and protein stability, both in vitro and in vivo, by CE-MS and LC-MS.

 

Your key learning objectives:

  • Learn how intact mass spectrometry of therapeutic proteins offers the highest possible resolution to assess protein/peptide integrity as well as post-translational modifications.
  • Learn the importance of protein purification prior to mass spectrometry analysis of therapeutic proteins in serum

This webinar will take place on Tuesday, June 9, at:

  • 16:00 BST
  • 17:00 CEST
  • 08:00 PDT
  • 11:00 EDT

This webinar is a part of the SelectScience Webinar Series: Drug Discovery and Complex Biology as well as the SelectScience Webinar Series: Advances in Mass Spectometry

SelectScience runs 3-4 webinars a month across various scientific topics, discover more of our upcoming webinars>>